Welcome to our dedicated page for Assertio Holdings news (Ticker: ASRT), a resource for investors and traders seeking the latest updates and insights on Assertio Holdings stock.
Assertio Holdings Inc operates as a specialty pharmaceutical company focused on neurology, pain management, and inflammation treatments. The company's news coverage primarily includes financial reports, clinical study results, regulatory developments, and corporate announcements relevant to investors tracking pharmaceutical industry developments.
Pharmaceutical company news typically encompasses earnings releases, product development updates, regulatory approvals, clinical trial outcomes, and licensing agreements. For Assertio, investors monitor quarterly financial performance, real-world evidence study results, product commercialization progress, and strategic partnerships that may impact the company's therapeutic portfolio. The company's focus on specialty pharmaceuticals means that news often relates to payer negotiations, formulary access, and prescriber adoption metrics.
Following pharmaceutical company developments requires attention to both company-specific announcements and broader industry trends affecting drug pricing, healthcare policy, and reimbursement dynamics. Material events filed with the SEC provide insight into significant business developments, while conference presentations and medical meetings offer updates on clinical programs and market strategies. Investors in specialty pharmaceutical companies analyze news for indicators of commercial execution, pipeline advancement, and market access achievements.
This news page aggregates announcements from Assertio Holdings, including material events, financial disclosures, and corporate updates. Regular monitoring helps investors understand the company's operational progress, competitive positioning within neurology and pain management markets, and strategic direction in an evolving healthcare landscape.
The Buxton Helmsley Group (BHG), a significant shareholder of Assertio Holdings (NASDAQ: ASRT), has issued a letter to the company's Board of Directors expressing grave concerns about its composition and performance. BHG calls for the immediate resignation of four directors, including Chairman Peter Staple, and criticizes the Board's failure to explain and recover damages from the value-destructive Spectrum Pharmaceuticals acquisition. The letter highlights issues such as the 75% write-down of Spectrum's value within three months of acquisition, inadequate due diligence, and a lack of specific expertise on the Board. BHG threatens a proxy contest and potential derivative litigation if no progress is made, intending to nominate independent, qualified directors at the next shareholder meeting.
Assertio Holdings, a pharmaceutical company listed on NASDAQ under the ticker ASRT, announced on July 9, 2024, the issuance of inducement grants to four new employees. Effective from July 1, 2024, these grants comprise 44,575 restricted stock units (RSUs) and 142,910 stock options. The inducement grants are made in accordance with NASDAQ Listing Rule 5635(c)(4) and are intended to encourage the new hires' entry into the company. The RSUs and options have terms similar to those in Assertio's 2014 Omnibus Incentive Plan. The stock options carry an exercise price of $1.19 per share, the closing price on the grant date, and will vest over three years starting from the first anniversary of the grant date.
Assertio Holdings has awarded its new CEO, Brendan P. O’Grady, 500,000 restricted stock units (RSUs) and 1,800,000 stock options as of May 31, 2024.
The stock options, which have an exercise price of $0.99 per share, and RSUs will vest equally over three years. These grants are in accordance with NASDAQ Listing Rule 5635(c)(4) and are material to Mr. O’Grady’s employment with Assertio.
Assertsio is a pharmaceutical company specializing in differentiated products.
Assertio Holdings, a pharmaceutical company known for its commercial capabilities and unique product offerings, announced its participation in the Sidoti Small Cap Conference on June 12, 2024. The event will be held virtually, with Ajay Patel, the Chief Financial Officer, presenting at 10:45 am Eastern Time. Investors can access the presentation through a webcast available on Assertio's investor relations website. Additionally, 1x1 meetings can be scheduled via Sidoti representatives or by contacting Assertio's investor relations.
On May 29, 2024, Assertio announced the appointment of Brendan P. O’Grady as the new CEO and a board member. O'Grady, with over 30 years in the pharmaceutical industry, has a strong record of accelerating sales growth and profitability. Most recently, he was CEO of Glenmark Pharmaceuticals' Global Formulations business, focusing on new product launches and market growth. His previous roles include key positions at Amwell and Teva Pharmaceuticals, where he drove significant growth and productivity. The Board expressed confidence in O'Grady's leadership to drive Assertio's strategic growth and diversification.
Assertio Holdings announced that CFO Ajay Patel will participate in the Benchmark & Company Healthcare House Call Virtual Conference on May 21-22, 2024. Assertio, listed on Nasdaq under the ticker ASRT, specializes in providing differentiated pharmaceutical products. Investors interested in scheduling a meeting can do so through their Benchmark representative or by contacting Assertio's investor relations.
The Buxton Helmsley Group (BHG), an investment fund manager, released a letter from Rumbi B. Petrozzello, a Certified Fraud Examiner, highlighting disclosure failures and deficiencies by the Board of Assertio Holdings (NASDAQ: ASRT). The letter presents significant concerns, urging stockholders to vote against all directors at the upcoming annual meeting on May 23, 2024. Petrozzello's analysis reveals issues like a steep 75% drop in intangible asset value post-Spectrum Pharmaceuticals acquisition, evasive responses from Assertio's management, and insufficient disclosures on contingent liabilities. BHG proposes independent investigation and has nominated Petrozzello to the Board, advocating for new oversight to protect investor interests.
Assertio Holdings (Nasdaq: ASRT), a pharmaceutical company, announced that its Chief Financial Officer, Ajay Patel, will present at the Alliance Global Partners Virtual Healthcare Company Showcase on May 21, 2024, at 3:40 p.m. Eastern Time. The presentation will provide an overview of Assertio's business and will be accessible through AGP's healthcare equity research team. Interested investors can join by contacting their AGP representative or Assertio investor relations. Further details will be available on the day of the event at https://investor.assertiotx.com.
The Buxton Helmsley Group (BHG) urges Assertio stockholders to vote against all director nominees at the upcoming annual meeting on May 23, 2024. BHG criticizes Assertio’s board for failing in oversight, inadequate disclosures, and poor strategic decisions, including a costly acquisition of Spectrum Pharmaceuticals. Analysts have dropped coverage of Assertio, citing a loss of faith in leadership. BHG proposes adding two new directors to bring better oversight and restore value for stockholders. The group also recommends strategic alternatives, including a possible sale to enhance operating profit.
Assertio Holdings, Inc. will present at the Citizens JMP Life Sciences Conference in New York City on May 13, 2024. Ajay Patel, Chief Financial Officer, will lead the presentation at 12:00 pm Eastern Time. Investors can request meetings with the Company through JMP representatives or contact Assertio investor relations. Presentation information will be available on the event day at https://investor.assertiotx.com. To listen to the webcast, connect to the website link 15 minutes before the live webcast.
FAQ
What is the current stock price of Assertio Holdings (ASRT)?
What is the market cap of Assertio Holdings (ASRT)?
